| pubmed-article:1450902 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1450902 | lifeskim:mentions | umls-concept:C0026809 | lld:lifeskim |
| pubmed-article:1450902 | lifeskim:mentions | umls-concept:C0027358 | lld:lifeskim |
| pubmed-article:1450902 | lifeskim:mentions | umls-concept:C0140057 | lld:lifeskim |
| pubmed-article:1450902 | lifeskim:mentions | umls-concept:C0002766 | lld:lifeskim |
| pubmed-article:1450902 | lifeskim:mentions | umls-concept:C0596130 | lld:lifeskim |
| pubmed-article:1450902 | pubmed:issue | 1-2 | lld:pubmed |
| pubmed-article:1450902 | pubmed:dateCreated | 1993-1-6 | lld:pubmed |
| pubmed-article:1450902 | pubmed:abstractText | The effects of naloxone on the analgesic response were examined using the tail-flick test, in mice with streptozotocin-induced diabetes. Subcutaneous injection of naloxone (5 mg/kg, s.c.) produced a marked analgesia in diabetic mice but not in age-matched non-diabetic mice. Naloxone-induced analgesia in diabetic mice was significantly reduced by pretreatment with naltrindole (0.1 mg/kg, s.c.), a selective antagonist of delta-opioid receptors. By contrast, no significant naloxone-induced increase in tail-flick latency in diabetic mice was observed after chronic treatment with naloxone (5 mg/kg, s.c.) for 5 days. However, the tail-flick latency was significantly increased by chronic treatment with naloxone in non-diabetic mice. Furthermore, the significant naloxone-induced increase in tail-flick latency in non-diabetic mice that had been chronically treated with naloxone was also antagonized by pretreatment with naltrindole. Chronic pretreatment with 5 mg/kg of naloxone for 5 days markedly attenuated the analgesic effect of the delta-agonist DPDPE in diabetic mice, whereas this pretreatment significantly enhanced the effect of DPDPE in non-diabetic mice. These results suggest that naloxone-induced 'paradoxical' analgesia in mice may be mediated predominantly by delta-opioid receptors. | lld:pubmed |
| pubmed-article:1450902 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1450902 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1450902 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1450902 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1450902 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1450902 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1450902 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1450902 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1450902 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1450902 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1450902 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:1450902 | pubmed:issn | 0006-8993 | lld:pubmed |
| pubmed-article:1450902 | pubmed:author | pubmed-author:KasuyaYY | lld:pubmed |
| pubmed-article:1450902 | pubmed:author | pubmed-author:KawashimaNN | lld:pubmed |
| pubmed-article:1450902 | pubmed:author | pubmed-author:KameiJJ | lld:pubmed |
| pubmed-article:1450902 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1450902 | pubmed:day | 2 | lld:pubmed |
| pubmed-article:1450902 | pubmed:volume | 592 | lld:pubmed |
| pubmed-article:1450902 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1450902 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1450902 | pubmed:pagination | 101-5 | lld:pubmed |
| pubmed-article:1450902 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:1450902 | pubmed:meshHeading | pubmed-meshheading:1450902-... | lld:pubmed |
| pubmed-article:1450902 | pubmed:meshHeading | pubmed-meshheading:1450902-... | lld:pubmed |
| pubmed-article:1450902 | pubmed:meshHeading | pubmed-meshheading:1450902-... | lld:pubmed |
| pubmed-article:1450902 | pubmed:meshHeading | pubmed-meshheading:1450902-... | lld:pubmed |
| pubmed-article:1450902 | pubmed:meshHeading | pubmed-meshheading:1450902-... | lld:pubmed |
| pubmed-article:1450902 | pubmed:meshHeading | pubmed-meshheading:1450902-... | lld:pubmed |
| pubmed-article:1450902 | pubmed:meshHeading | pubmed-meshheading:1450902-... | lld:pubmed |
| pubmed-article:1450902 | pubmed:meshHeading | pubmed-meshheading:1450902-... | lld:pubmed |
| pubmed-article:1450902 | pubmed:meshHeading | pubmed-meshheading:1450902-... | lld:pubmed |
| pubmed-article:1450902 | pubmed:meshHeading | pubmed-meshheading:1450902-... | lld:pubmed |
| pubmed-article:1450902 | pubmed:meshHeading | pubmed-meshheading:1450902-... | lld:pubmed |
| pubmed-article:1450902 | pubmed:meshHeading | pubmed-meshheading:1450902-... | lld:pubmed |
| pubmed-article:1450902 | pubmed:meshHeading | pubmed-meshheading:1450902-... | lld:pubmed |
| pubmed-article:1450902 | pubmed:meshHeading | pubmed-meshheading:1450902-... | lld:pubmed |
| pubmed-article:1450902 | pubmed:meshHeading | pubmed-meshheading:1450902-... | lld:pubmed |
| pubmed-article:1450902 | pubmed:meshHeading | pubmed-meshheading:1450902-... | lld:pubmed |
| pubmed-article:1450902 | pubmed:meshHeading | pubmed-meshheading:1450902-... | lld:pubmed |
| pubmed-article:1450902 | pubmed:meshHeading | pubmed-meshheading:1450902-... | lld:pubmed |
| pubmed-article:1450902 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1450902 | pubmed:articleTitle | Paradoxical analgesia produced by naloxone in diabetic mice is attributable to supersensitivity of delta-opioid receptors. | lld:pubmed |
| pubmed-article:1450902 | pubmed:affiliation | Department of Pharmacology, Faculty of Pharmaceutical Sciences, Hoshi University, Tokyo, Japan. | lld:pubmed |
| pubmed-article:1450902 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1450902 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1450902 | lld:pubmed |
